Characterisation of the antidepressant properties of nitric oxide synthase inhibitors in the olfactory bulbectomised rat model of depression

Nitric oxide synthase (NOS) inhibitors possess antidepressant-like properties in preclinical tests and in the current investigation the brain penetrant NOS inhibitor N(ω)-nitro-L-arginine (l-NA) and the preferential inhibitor of neuronal NOS (nNOS) 1-(2-trifluoromethylphenyl) imidazole (TRIM) were assessed in the olfactory bulbectomised (OB) rat, a well-established animal model of depression. Magnetic resonance imaging (MRI) was employed to assess regional brain volumes, blood perfusion and T1 and T2 relaxometry times both with and without drug treatment. l-NA (10 mg/kg, once daily p.o. for 10 days) attenuated OB-related hyperactivity in the "open field" test in a comparable fashion to the tricyclic antidepressant imipramine (20 mg/kg, once daily p.o. for 14 days) indicative of an antidepressant-like response in the model. Treatment with TRIM (50 mg/kg, once daily s.c.) attenuated OB-related hyperactivity following 7 days of treatment when compared to vehicle treated controls. OB is associated with enlarged ventricular volume, increased periventicular perfusion and a decrease in T2 relaxation times in cortical and hippocampal regions, with enhanced perfusion and reduced T2 times attenuated by L-NA treatment. L-NA treatment was also associated with an increase in T1 relaxation times in limbic and cortical regions and found to reduce resting state hippocampal blood perfusion in OB animals. Behavioural observations are consistent with an antidepressant action of NOS inhibitors where associated changes in perfusion and T2 relaxation times may be related to the antidepressant action of L-NA in the model.

[1]  B. Leonard,et al.  The olfactory bulbectomised rat as a model of depression , 2005, Neuroscience & Biobehavioral Reviews.

[2]  Nanxin Li,et al.  mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists , 2010, Science.

[3]  Kyooseob Ha,et al.  Inhibitory effect of the antidepressant imipramine on NF-κB-dependent CXCL1 expression in TNFα-exposed astrocytes. , 2012, International immunopharmacology.

[4]  Carlos A. Zarate,et al.  Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders , 2008, Nature Reviews Drug Discovery.

[5]  B. Leonard,et al.  Anatomical, physiological, and behavioral aspects of olfactory bulbectomy in the rat. , 1981, International review of neurobiology.

[6]  Steven C. R. Williams,et al.  The neuronal nitric oxide synthase inhibitor, TRIM, as a neuroprotective agent: effects in models of cerebral ischaemia using histological and magnetic resonance imaging techniques , 2003, Brain Research.

[7]  L. Eng,et al.  GFAP and Astrogliosis , 1994, Brain pathology.

[8]  P. K. Moore,et al.  Effects of selective inhibitors of neuronal nitric oxide synthase on carrageenan-induced mechanical and thermal hyperalgesia , 1998, Neuropharmacology.

[9]  C. Zarate,et al.  Ketamine and the next generation of antidepressants with a rapid onset of action. , 2009, Pharmacology & therapeutics.

[10]  A role for cGMP-dependent protein kinase II in AMPA receptor trafficking and synaptic plasticity , 2008 .

[11]  A. Simmons,et al.  Structural neuroimaging studies in major depressive disorder. Meta-analysis and comparison with bipolar disorder. , 2011, Archives of general psychiatry.

[12]  James M. O'Donnell,et al.  A study of VitalView™ for behavioural and physiological monitoring in laboratory rats , 2002, Physiology & Behavior.

[13]  Christian M Kerskens,et al.  Quantitative Functional Magnetic Resonance Imaging of Brain Activity Using Bolus-Tracking Arterial Spin Labeling , 2010, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[14]  A. Becker,et al.  Cell Proliferation is Influenced by Bulbectomy and Normalized by Imipramine Treatment in a Region-Specific Manner , 2006, Neuropsychopharmacology.

[15]  M. Bourin,et al.  Antidepressant- and anxiolytic-like effects of selective neuronal NOS inhibitor 1-(2-trifluoromethylphenyl)-imidazole in mice , 2003, Behavioural Brain Research.

[16]  Christoph W. Blau,et al.  Rosiglitazone attenuates the age-related changes in astrocytosis and the deficit in LTP , 2012, Neurobiology of Aging.

[17]  Christoph W. Blau,et al.  The age-related deficit in LTP is associated with changes in perfusion and blood-brain barrier permeability , 2012, Neurobiology of Aging.

[18]  Christoph W. Blau,et al.  Bolus-tracking arterial spin labelling: theoretical and experimental results , 2009, Physics in medicine and biology.

[19]  R. Koehler,et al.  Astrocytes and the regulation of cerebral blood flow , 2009, Trends in Neurosciences.

[20]  Marcus E Raichle,et al.  Glucose metabolism in the amygdala in depression: Relationship to diagnostic subtype and plasma cortisol levels , 2002, Pharmacology Biochemistry and Behavior.

[21]  F. Franconi,et al.  An in-vivo magnetic resonance imaging study of the olfactory bulbectomized rat model of depression , 2000, Brain Research.

[22]  Mathias Hoehn,et al.  MRI Detection of Secondary Damage After Stroke: Chronic Iron Accumulation in the Thalamus of the Rat Brain , 2008, Stroke.

[23]  J. Kelly,et al.  A review of the relevance and validity of olfactory bulbectomy as a model of depression , 2003, Clinical Neuroscience Research.

[24]  J. Kelly,et al.  Behavioural and Neurochemical Effects of Dizocilpine in the Olfactory Bulbectomized Rat Model of Depression , 1997, Pharmacology Biochemistry and Behavior.

[25]  G. B. Wisely,et al.  NF-kappa B regulates IL-1 beta transcription through a consensus NF-kappa B binding site and a nonconsensus CRE-like site. , 1994, Journal of immunology.

[26]  S. Kulkarni,et al.  Nitric oxide and major depression. , 2011, Nitric oxide : biology and chemistry.

[27]  M. Raichle,et al.  Functional anatomical correlates of antidepressant drug treatment assessed using PET measures of regional glucose metabolism , 2002, European Neuropsychopharmacology.

[28]  R. Duman,et al.  Signaling pathways underlying the pathophysiology and treatment of depression: novel mechanisms for rapid-acting agents , 2012, Trends in Neurosciences.

[29]  Klaus P. Ebmeier,et al.  Magnetic resonance imaging studies in unipolar depression: Systematic review and meta-regression analyses , 2012, European Neuropsychopharmacology.

[30]  M. Doucet,et al.  Small-Molecule Inhibitors at the PSD-95/nNOS Interface have Antidepressant-Like Properties in Mice , 2013, Neuropsychopharmacology.

[31]  P. Skolnick,et al.  Glutamate-based antidepressants: 20 years on. , 2009, Trends in pharmacological sciences.

[32]  Susumu Mori,et al.  Structural insights into the rodent CNS via diffusion tensor imaging , 2012, Trends in Neurosciences.

[33]  Andrew M Blamire,et al.  Acute Astrocyte Activation in Brain Detected by Mri: New Insights into T1 Hypointensity , 2008, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[34]  S. Moncada,et al.  Nitric oxide: physiology, pathophysiology, and pharmacology. , 1991, Pharmacological reviews.

[35]  T. Connor,et al.  MDMA ("Ecstasy") suppresses the innate IFN-gamma response in vivo: a critical role for the anti-inflammatory cytokine IL-10. , 2007, European journal of pharmacology.

[36]  M. Banasr,et al.  Glial Loss in the Prefrontal Cortex Is Sufficient to Induce Depressive-like Behaviors , 2008, Biological Psychiatry.

[37]  M. Furey,et al.  Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression , 2008, Brain Structure and Function.

[38]  J. Kelly,et al.  Chronic Fluoxetine Treatment Attenuates Stressor-Induced Changes in Temperature, Heart Rate, and Neuronal Activation in the Olfactory Bulbectomized Rat , 2007, Neuropsychopharmacology.

[39]  S. Chaki,et al.  Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression , 2011, Behavioural Brain Research.

[40]  C. Ouimet,et al.  Altered dendritic spine density in animal models of depression and in response to antidepressant treatment , 2001, Synapse.

[41]  G. Rajkowska,et al.  Depression: What We can Learn from Postmortem Studies , 2003, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[42]  J. Kelly,et al.  Activity and onset of action of reboxetine and effect of combination with sertraline in an animal model of depression. , 1999, European journal of pharmacology.

[43]  F. X. Guix,et al.  The physiology and pathophysiology of nitric oxide in the brain , 2005, Progress in Neurobiology.

[44]  E. Bora,et al.  Gray matter abnormalities in Major Depressive Disorder: a meta-analysis of voxel based morphometry studies. , 2012, Journal of affective disorders.

[45]  B. Ravnkilde,et al.  Hippocampal volume and depression: a meta-analysis of MRI studies. , 2004, The American journal of psychiatry.

[46]  Guang Chen,et al.  Cellular Mechanisms Underlying the Antidepressant Effects of Ketamine: Role of α-Amino-3-Hydroxy-5-Methylisoxazole-4-Propionic Acid Receptors , 2008, Biological Psychiatry.

[47]  S. Goyal,et al.  Neuropeptide Y modulates the antidepressant activity of imipramine in olfactory bulbectomized rats: Involvement of NPY Y1 receptors , 2009, Brain Research.

[48]  G. Sanacora,et al.  Beyond Monoamines: Glutamatergic Function in Mood Disorders , 2005, CNS Spectrums.

[49]  Dost Öngür,et al.  Magnetic Resonance Spectroscopy Studies of Glutamate-Related Abnormalities in Mood Disorders , 2010, Biological Psychiatry.

[50]  Yogesh K. Dwivedi,et al.  Pharmacological properties of glutamatergic drugs targeting NMDA receptors and their application in major depression. , 2013, Current pharmaceutical design.

[51]  J. Kelly,et al.  The olfactory bulbectomized rat as a model of depression: an update. , 1997, Pharmacology & therapeutics.

[52]  A. Harkin,et al.  A role for serotonin in the antidepressant activity of NG-Nitro-L-arginine, in the rat forced swimming test , 2010, Pharmacology Biochemistry and Behavior.

[53]  A. Villringer,et al.  Mapping the depressed brain: a meta-analysis of structural and functional alterations in major depressive disorder. , 2012, Journal of affective disorders.

[54]  G. Paxinos,et al.  The Rat Brain in Stereotaxic Coordinates , 1983 .

[55]  Bin Wang,et al.  Neuronal nitric oxide synthase contributes to chronic stress‐induced depression by suppressing hippocampal neurogenesis , 2007, Journal of neurochemistry.

[56]  J. Qu,et al.  Protective effects of imipramine in murine endotoxin-induced acute lung injury. , 2010, European journal of pharmacology.

[57]  R. Kalisch,et al.  Anxiety and Hippocampus Volume in the Rat , 2006, Neuropsychopharmacology.

[58]  R. Oosting,et al.  Antidepressant effects of pramipexole, a dopamine D3/D2 receptor agonist, and 7-OH-DPAT, a dopamine D3 receptor agonist, in olfactory bulbectomized rats. , 2009, European journal of pharmacology.

[59]  K. Suk,et al.  NF-κB as a common signaling pathway in ganglioside-induced autophagic cell death and activation of astrocytes , 2010, Journal of Neuroimmunology.

[60]  C. Belzung,et al.  Effects of neuronal and inducible NOS inhibitor 1-[2-(trifluoromethyl) phenyl] imidazole (TRIM) in unpredictable chronic mild stress procedure in mice , 2009, Pharmacology Biochemistry and Behavior.

[61]  H. Zeumer,et al.  MRI abnormalities in normal‐appearing brain tissue of treated adult PKU patients , 2008, Journal of magnetic resonance imaging : JMRI.